Total Funding
44
56
Total FundingSeries B raised
Growth Score
-4 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
49663
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.
- Alan Naylor: Co-FounderPast Role: GlaxoSmithKline, Vice President and Director of Medicinal Chemistry
- Tom McCarthy: Co-FounderPast Role: Spinifex Pharmaceuticals, Chief Executive Officer & Managing Director
About the Company
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer. Pathios Therapeutics concentrates on the development of small molecule inhibitors targeting the pH-sensing G protein-coupled receptor GPR65. These inhibitors aim to counteract the immunosuppressive polarization of immune cells, such
as tumor-associated macrophages, mediated by GPR65. This polarization is stimulated by the acidic tumor microenvironment commonly found in various cancers.
